Last Thursday (June 28), a medical cannabis company with business in the US and Canada received a rating and one-year price predictions from one of the leading cannabis banking firms.

Canaccord Genuity started its coverage of Sunniva (CSE:SNN) off by slapping the company with a “Speculative Buy” rating on its stock and a one year price target of C$7.80. Sunniva’s previous closing price on Tuesday (July 3) was C$8.10.


Sunniva owns a late stage applicant to legally grow medical cannabis in Canada, with the plans to develop a 700,000 square feet greenhouse facility–the Sunniva Canada Campus– with a target production of 100,000 kilograms of cannabis product at this facility, according to the report.

In addition to the Suniva Canada Campus the company  Sunniva is also focused in the California market with the construction of a greenhouse facility expected to produce an additional 100,000 kilograms of cannabis per year.

“Although we believe our individual valuations are built on relatively conservative assumptions, the core value driver of our model rests in the assumed market penetration Sunniva will ultimately be able to secure in California and Canada,” the note from Canaccord analyst Matt Bottomley said.

As part of its Q1 financial results, Sunniva indicated it had obtained a confirmation of readiness from Health Canada about its licensed producer (LP) application.

The company also owns Natural Health Services, a cannabis clinic operator with seven locations in Canada offering patient consultations and has a 95,000 patient base, according to the note.

In February Sunniva signed a supply agreement with Canopy Growth (TSX:WEED;NYSE:CGC) to provide 45,000 kilograms of dried cannabis annually. Leith Pedersen, president of Sunniva, said by making this partnership the company was “de-risking” its business model.

According to the data presented by the report the company holds a “SOTP” (sum-of-the-parts) valuation of C$13.08 per share.

Bottomley wrote he believes Sunniva will have to “secure a portion of its market share in its own branded products to cement a longer-term market position and to safeguard against margin compression.”

Canaccord cited the potential for the company to not achieve its projected production capacity as a significant risk for Sunniva’s Canadian operations.

US interest for the company adds value due to right momentum in the country

Despite holding an interest in the often volatile US cannabis market, Canaccord believes the momentum is swinging right for the drug at the moment, particularly in California with the legalization of adult-use cannabis this year.

As a whole, cannabis companies with US assets have been forced to raise capital in the Canadian Securities Exchange (CSE) due to the lighter restrictions around the interests below the border.

During panel at the Vancouver edition of the International Cannabis Business Conference (ICBC) Anna Serin, director of listings development for the CSE, told the crowd over the past year 58 percent of the capital raised by CSE-listed companies, close to C$2 billion, was in cannabis.

Since the report was issued to investors last Thursday the company’s stock has increased in value by 4.65 percent and is finished Wednesday’s (July 4) trading session at a price of C$8.10 per share.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less